TITLE

Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease

AUTHOR(S)
Regueiro, Miguel; Valentine, John; Plevy, Scott; Fleisher, Mark R.; Lichtenstein, Gary R.
PUB. DATE
August 2003
SOURCE
American Journal of Gastroenterology;Aug2003, Vol. 98 Issue 8, p1821
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
: ObjectivesPyoderma gangrenosum is an immune-mediated inflammatory condition characterized by ulcerative skin lesions affecting 1–2% of patients with inflammatory bowel disease (IBD). Treatment includes wound care, antibiotics, corticosteroids, and immunomodulators. However, response to therapy varies, and many patients with pyoderma gangrenosum have disease that is refractory to these agents. The aim of this study was to assess the response of medically refractory pyoderma gangrenosum to infliximab.: MethodsThis was a multicenter retrospective study of patients with IBD and medically refractory pyoderma gangrenosum treated with infliximab. Data collected included the following: baseline demographics; duration of IBD; history of bowel resection; duration of skin lesions; number, size, and location of pyoderma gangrenosum lesions; prior medications; dose and number of infliximab infusions; bowel activity before and after infliximab; pyoderma gangrenosum activity before and after infliximab therapy; time to response and time to healing of pyoderma gangrenosum lesions; recurrence of pyoderma gangrenosum after infliximab; corticosteroid taper; and adverse reactions to infliximab.: ResultsThere were 13 patients with moderate to severe pyoderma gangrenosum and IBD treated with infliximab. All patients demonstrated complete healing of the skin lesions. Three patients had a complete response to induction infliximab therapy and did not require additional treatment. Ten patients responded to induction infliximab and have maintained pyoderma gangrenosum healing with infusions every 4–12 wk. All patients receiving corticosteroids were able to discontinue them completely after institution of infliximab treatment. Infliximab was well tolerated; the only treatment-related adverse events were sunburn in one patient and an infusion reaction in another.: ConclusionInfliximab is a safe and effective treatment for IBD-associated pyoderma gangrenosum.
ACCESSION #
10428282

 

Related Articles

  • Case study: diagnosis and treatment of pyoderma gangrenosum. Burton, Julie // British Journal of Nursing;9/8/2005, Vol. 14 Issue 16, pS10 

    Pyoderma gangrenosum, is an ulcerative, inflammatory disorder often associated in the field of stoma care with inflammatory bowel disease (IBD) (Lyon and Smith, 2001). Pyoderma gangrenosum is distinctive in that it normally has a purple rolled edge and is extremely painful. The pathogenesis is...

  • The Immunological Basis of Inflammatory Bowel Disease. Silva, Francesca A. R.; Rodrigues, Bruno L.; Ayrizono, Maria de Lourdes S.; Leal, Raquel F. // Gastroenterology Research & Practice;12/14/2016, p1 

    Inflammatory bowel diseases (IBDs) are chronic ailments, Crohn’s disease and ulcerative colitis being the most important. These diseases present an inflammatory profile and they differ according to pathophysiology, the affected area in the gastrointestinal tract, and the depth of the...

  • Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease. Trikudanathan, Guru; Vankatesh, Preethi G.k.; Navaneethan, Udayakumar // Drugs;2012, Vol. 72 Issue 18, p2333 

    Extra-intestinal manifestations (EIMs) are reported frequently in patients with inflammatory bowel disease (IBD) and may be diagnosed before, concurrently or after the diagnosis of IBD. EIMs in IBD may be classified based on their association with IBD disease activity. The first group has a...

  • Acute distal colitis impairs gastric emptying in rats via an extrinsic neuronal reflex pathway involving the pelvic nerve. De Schepper, H. U.; De Man, I. G.; Van Nassauw, I.; Timmermans, J.-P.; Herman, A. G.; Pelckmans, P. A.; De Winter, B. Y. // Gut;Feb2007, Vol. 56 Issue 2, p195 

    Background and aims: Patients with inflammatory bowel disease often present with abnormal gut motility away from the inflammatory site. We studied remote motility disturbances and their pathophysiology in a rat model of colitis. Methods: Colitis was induced 72 h prior to experiments using...

  • Pre- and Posttherapy Assessment of Intestinal Soluble Mediators in IBD: Where We Stand and Future Perspectives. Scaldaferri, F.; Petito, V.; Lopetuso, L.; Bruno, G.; Gerardi, V.; Ianiro, G.; Sgambato, A.; Gasbarrini, A.; Cammarota, G. // Mediators of Inflammation;2013, Vol. 2013, p1 

    Inflammatory bowel disease (IBD) is a chronic inflammatory condition characterized by an abnormal immune response against food or bacterial antigens in genetically predisposed individuals. Several factors of innate and adaptive immune system take part in the inflammatory process, probably...

  • CIRCULATING TUMOUR NECROSIS FACTOR ALPHA CONCENTRATIONS AND PERIPHERAL CD4[sup +] T CELL CHEMOKINE RECEPTOR EXPRESSION IN PATIENTS WITH PYODERMA GANGRENOSUM. Brooklyn, T.N.; Williams, A.M.; Probert, C.S. // Gut;Apr2003 Supplement 1, Vol. 52, pA61 

    Background: Pyoderma gangrenosum (PG) is recognised as an extraintestinal manifestation of inflammatory bowel disease (IBD). Recent reports of PG responding to infliximab suggest that tumour necrosis factor alpha (TNF6) may be important, although in our hands the response of PG to infliximab has...

  • Inflammatory bowel disease: patients' expectations in the 1990s. Probert, C. S. J.; Mayberry, J. F. // Journal of the Royal Society of Medicine;Mar1991, Vol. 84 Issue 3, p131 

    A group of 70 patients with inflammatory bowel disease were asked to complete a questionnaire about their disease counselling preferences, 59 replied. Seventy-five per cent wanted further advice about their disease. Of these, 60% wished to receive the advice by discussion with a trained advisor....

  • seroenteritis.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2105 

    A definition of the term "seroenteritis" which refers to an inflammation of the serous layer of the intestine is presented.

  • Heightened Responses to Stressors in Patients with Inflammatory Bowel Disease. Farhadi, Ashkan; Keshavarzian, Ali; van de Kar, Louis D.; Jakate, Shriram; Domm, Aaron; Lei Zhang; Shaikh, Maliha; Banan, Ali; Fields, Jeremy Z. // American Journal of Gastroenterology;Aug2005, Vol. 100 Issue 8, p1796 

    OBJECTIVES: Several studies suggest that stressful situations (stressors) worsen the course of inflammatory bowel disease (IBD), but the mechanism is not known. Based on several lines of evidence, we hypothesized that psychosocial stress activates the brain-gut axis (BGA) and mucosal mast cells...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics